Detalhe da pesquisa
1.
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
Value Health
; 23(10): 1281-1285, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33032770
2.
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial.
Value Health
; 23(10): 1286-1291, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33032771
3.
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
Gastroenterology
; 155(4): 1008-1011.e8, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29981298
4.
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
Ann Rheum Dis
; 77(1): 21-29, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28507219
5.
Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
Ann Rheum Dis
; 73(12): 2152-9, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24001888
6.
Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-Onset and Adult-Onset Disease.
J Crohns Colitis
; 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38408273
7.
Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
Ann Rheum Dis
; 72(3): 381-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22661646
8.
Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
Rheumatol Ther
; 10(4): 983-999, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37322274
9.
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Arthritis Rheum
; 62(4): 917-28, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20131276
10.
The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.
Clin Rheumatol
; 40(9): 3667-3677, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33655380
11.
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
Clin Rheumatol
; 40(4): 1331-1341, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926247
12.
Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study.
ACR Open Rheumatol
; 2(11): 640-647, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33073933
13.
Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.
Arthritis Care Res (Hoboken)
; 72(6): 806-813, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30980514
14.
Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
J Rheumatol
; 46(6): 595-602, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770519
15.
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
J Rheumatol
; 46(10): 1277-1283, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30824635
16.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Lancet Neurol
; 7(9): 796-804, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18703004
17.
Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
J Rheumatol
; 45(3): 341-348, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29247154
18.
Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
Arthritis Rheumatol
; 69(11): 2151-2161, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28805045
19.
Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.
Clin Ther
; 37(2): 427-38, 2015 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25438720
20.
Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
Arthritis Care Res (Hoboken)
; 67(12): 1627-36, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25623393